Loading organizations...
§ Private Profile · Cambridge, MA, USA
Lila Sciences is a technology company.
Lila Sciences builds a scientific superintelligence platform, integrating advanced AI with autonomous laboratory instruments for accelerated discovery. This system autonomously generates hypotheses, designs and executes experiments, learning from new data in real-time. This approach fundamentally enhances the speed and scale at which scientific breakthroughs are identified across various domains.
Co-founded by Geoffrey von Maltzhan, Lila Sciences emerged from stealth in March 2024, driven by the insight that AI and autonomous systems can redefine the scientific method. Maltzhan, who co-founded successful Flagship Pioneering ventures, recognized the need for a more efficient, scalable discovery paradigm in research.
Lila Sciences' platform serves scientists and organizations in advanced materials, therapeutics, and energy, addressing complex research challenges. The company envisions building and sharing scientific superintelligence globally, fostering discoveries and accelerating novel solutions. Its mission is to push scientific frontiers, contributing to solving humanity's greatest problems.
Lila Sciences has raised $440.0M across 2 funding rounds.
Lila Sciences has raised $440.0M in total across 2 funding rounds.
Lila Sciences has raised $440.0M across 2 funding rounds. Most recently, it raised $240.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $240M Series A | — | 8VC, Alumni Ventures, Altitude Life Science Ventures, Bascom Ventures, Analog Devices, ARK Venture Fund, Braidwell, Catalio Capital, Dara Holdings, Dauntless Ventures, Flagship Pioneering, General Catalyst, IN Q TEL, March Capital, Mathers Foundation, Modi Ventures, NGS Super, NVIDIA, Pennant Investors, State OF Michigan Retirement System | Announced |
| Mar 12, 2025 | $200M Seed | — | ABU Dhabi Investment Authority, Altitude Life Science Ventures, ARK Venture Fund, Blue Horizon Advisors, Geoffrey VON Maltzahn, General Catalyst, March Capital, Modi Ventures, State OF Michigan Retirement System | Announced |
Lila Sciences has raised $440.0M in total across 2 funding rounds.
Lila Sciences's investors include 8VC, Alumni Ventures, Altitude Life Science Ventures, Analog Devices, ARK Venture Fund, Braidwell, Catalio Capital Management, Dara Holdings, Dauntless Ventures, Flagship Pioneering, General Catalyst, In-Q-Tel.
Lila Sciences is an early-stage technology company building the world's first scientific superintelligence platform paired with autonomous AI Science Factories for accelerated discovery in life sciences, chemistry, and materials science.[1][2][3] Its core product, the Autonomous Science platform, integrates generative AI for hypothesis generation, experiment design, and analysis with robotic labs that execute physical experiments in a closed-loop system, continuously learning from results to refine discoveries and produce novel therapeutics, compounds, and materials.[1][2][3][4] The platform serves enterprise partners, researchers, and industries like biotech, energy, and semiconductors by bridging AI predictions with real-world validation, addressing inefficiencies in traditional science such as reproducibility issues and slow experimentation.[1][5] Backed by Flagship Pioneering, Lila has raised approximately $550 million, including a $350 million Series A at over $1.3 billion valuation, fueling rapid growth with demonstrated benchmarks exceeding human and existing AI performance in antibody discovery, genetic medicines, and catalysts.[3][4][5]
Lila Sciences was founded in 2023 within the innovation labs of Flagship Pioneering, a bioplatform company known for creating ventures like Moderna.[3][4] Key figures include CEO Geoffrey von Maltzahn, formerly of Generate Biomedicines, and Molly Gibson, president of future science and co-founder ties via Flagship, who emphasize building an "intelligence operating system for science" through AI, robotics, and labs.[3][4][5][6] The idea emerged from Flagship's recognition of science's core bottleneck: the gap between AI predictions and physical validation amid a reproducibility crisis and inefficient knowledge sharing.[1][3] Lila emerged from stealth in March 2025 with a $200 million seed, quickly scaling via a $350 million Series A led by investors like Nvidia and In-Q-Tel, marking pivotal early traction through superior benchmarks in multi-domain experiments.[3][4][5]
Lila rides the wave of AI's evolution from data consumption to data generation, addressing finite internet datasets by creating real-world scientific data through autonomous experimentation, enabling "scientific superintelligence" to solve grand challenges in health and sustainability.[3][5] Timing aligns with 2025's AI lab boom, post-protein folding advances, amid U.S. priorities in semiconductors, energy, and biotech competitiveness, accelerated by investors like In-Q-Tel and Nvidia.[5] Market forces favoring Lila include science's reproducibility crisis, rising R&D costs, and demand for faster cycles in drug discovery and materials, positioning it to influence the ecosystem by compounding knowledge, reducing redundancy, and powering a programmable scientific method for broader innovation.[1][2][4]
Lila Sciences is poised to scale its AI Science Factories into a ubiquitous platform, expanding Cambridge facilities and partnerships to deliver licensed therapeutics, catalysts, and materials at unprecedented speed.[4][5] Trends like multimodal AI-physical integration and self-play experimentation will amplify its edge, potentially evolving it into the foundational OS for all science R&D amid growing AI verification needs.[4][6] As the divide between prediction and validation narrows, Lila could redefine discovery, amplifying Flagship's legacy from mRNA vaccines to autonomous science.